Dr. Christopher Anthony Carlos, MD

Dr. Carlos practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Carlos' NPI, 1457693921, was assigned on March 22, 2013. Dr. Carlos graduated from Cleveland Medical College, Homeopathic in 2013. Dr. Carlos holds California license A134161.

Dr. Carlos' primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Carlos' primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Carlos to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carlos practices. Vendor and product names are available with a free account.

Nephrology is Dr. Carlos' primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Carlos is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Carlos' licenses on file in 2 states: California and Ohio.

Dmand AI lists acute kidney failure, chronic hypertension, chronic kidney disease, fluid and electrolyte imbalances, gout, hypercalcemia, kidney disease and low blood pressure among the conditions Dr. Carlos treats.

CMS data shows 620 Medicare services from Dr. Carlos across 10 procedure codes in 2024, for 190 Medicare patients. Medicare paid $39,884 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 190 Medicare patients who saw Dr. Carlos in 2024. The largest group is 75 to 84, with 72 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 39% are also on Medicaid. Their average risk score is 4.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carlos' median patient age at 65, with 50% women.

In 2024, Dr. Carlos wrote 771 Medicare Part D claims for 119 patients. 81% of them were for generic drugs. CMS names the drug for 623 of them, across 23 drugs with 11 or more claims each, at $148,514 in total drug cost. In 2023, CMS named 615 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Carlos for performance year 2024, reported as part of a group. Dr. Carlos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carlos as offering telehealth.

Dmand AI links 9 papers to Dr. Carlos, published from 2017 to 2024. 2024 was the busiest year, with 2. The most frequent topics are Acute Kidney Injury, Immune Checkpoint Inhibitors and Immunotherapy. Dr. Carlos has published most often in J Immunother Cancer. Dr. Carlos' most frequent co-authors are Ala Abudayyeh, MD, Jason M. Prosek, MD and Arash Rashidi, MD.

Dmand AI links Dr. Carlos to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Glomerulonephritis, IGA and Glomerulonephritis.

CMS Open Payments shows 27 general payments to Dr. Carlos from 5 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 44% of the total. Calliditas Therapeutics US Inc. paid the most, $4,138.

Dr. Carlos graduated from Cleveland Medical College, Homeopathic in 2013.

Dr. Carlos is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.